EMAIL THIS PAGE TO A FRIEND

Toxicological sciences : an official journal of the Society of Toxicology

Ovarian xenobiotic biotransformation enzymes are altered during phosphoramide mustard-induced ovotoxicity.


PMID 25070981

Abstract

The anti-neoplastic prodrug, cyclophosphamide, requires biotransformation to phosphoramide mustard (PM), which partitions to volatile chloroethylaziridine (CEZ). PM and CEZ are ovotoxicants, however their ovarian biotransformation remains ill-defined. This study investigated PM and CEZ metabolism mechanisms through the utilization of cultured postnatal day 4 (PND4) Fisher 344 (F344) rat ovaries exposed to vehicle control (1% dimethyl sulfoxide (DMSO)) or PM (60μM) for 2 or 4 days. Quantification of mRNA levels via an RT(2) profiler PCR array and target-specific RT-PCR along with Western blotting found increased mRNA and protein levels of xenobiotic metabolism genes including microsomal epoxide hydrolase (Ephx1) and glutathione S-transferase isoform pi (Gstp). PND4 ovaries were treated with 1% DMSO, PM (60μM), cyclohexene oxide to inhibit EPHX1 (CHO; 2mM), or PM + CHO for 4 days. Lack of functional EPHX1 increased PM-induced ovotoxicity, suggesting a detoxification role for EPHX1. PND4 ovaries were also treated with 1% DMSO, PM (60μM), BSO (Glutathione (GSH) depletion; 100μM), GEE (GSH supplementation; 2.5mM), PM ± BSO, or PM ± GEE for 4 days. GSH supplementation prevented PM-induced follicle loss, whereas no impact of GSH depletion was observed. Lastly, the effect of ovarian GSH on CEZ liberation and ovotoxicity was evaluated. Both untreated and GEE-treated PND4 ovaries were plated adjacent to ovaries receiving PM + GEE or PM + BSO treatments. Less CEZ-induced ovotoxicity was observed with both GEE and BSO treatments indicating reduced CEZ liberation from PM. Collectively, this study supports ovarian biotransformation of PM, thereby influencing the ovotoxicity that ensues.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1405765
Anti-EPHX1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV54286
Anti-EPHX1 antibody produced in rabbit, affinity isolated antibody
HPA020593
Anti-EPHX1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA019779
Anti-GSTP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab1
HPA019869
Anti-GSTP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab2
SAB3500265
Anti-GSTP1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
WH0002052M1
Monoclonal Anti-EPHX1 antibody produced in mouse, clone 2E7, purified immunoglobulin, buffered aqueous solution
SAB1403785 Monoclonal Anti-EPHX1 antibody produced in mouse, clone 2B1, purified immunoglobulin, buffered aqueous solution
SAB4100494
Monoclonal Anti-EPHX1 antibody produced in mouse, clone EPHX1-B414, culture supernatant
SAB1402216
Monoclonal Anti-GSTM2 antibody produced in mouse, clone 1E10, purified immunoglobulin, buffered aqueous solution
WH0002950M1
Monoclonal Anti-GSTP1 antibody produced in mouse, clone 2G6-F6, purified immunoglobulin, buffered aqueous solution
SAB1403891
Monoclonal Anti-GSTP1 antibody produced in mouse, clone S1, purified immunoglobulin, buffered aqueous solution
SAB5300454
Monoclonal Anti-GSTP1 antibody produced in mouse, clone 3F2C2, ascites fluid